#6
Eli Lilly (LLY)
The pharmaceutical giant saw its stock surge over 800% as its GLP-1 drugs Mounjaro and Zepbound created an entirely new blockbuster weight-loss medication category, outperforming #10 Eli Lilly's earlier pipeline expectations and capturing over 90% of the GLP-1 market share in 2024. This return is double that of Amazon's 500%, and combined Mounjaro and Zepbound sales exceeded $12 billion in 2023, over 30% more than the entire diabetes drug category average.
0
Photos (1)
Comments on "Eli Lilly (LLY)"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.